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The basics
A randomised controlled trial (RCT), also known as a randomised
controlled clinical trial, is a study in which participants are
assigned randomly to one of two or more arms (groups with
different interventions) of a clinical trial. Occasionally, a placebo is
used as one of the interventions, but, generally, if there is a
recognised and accepted intervention that works (the “gold
standard”), then a new drug, device or intervention is tested
against this gold standard rather than against placebo. Where a
gold standard drug or intervention exists, it would be unethical to
randomise to a placebo and, by doing so, make an effective
treatment unavailable to some participants. Generally, RCTs are
conducted because there is equipoise (or uncertainty) about
whether a new intervention is potentially better than an existing
one. The trialists (the team of people that plan, conduct, supervise
and analyse the results of the trial) start with the hypothesis that
there is no difference between the two interventions (this is “the
null hypothesis”). The purpose of the RCT is to reject or accept
the null hypothesis. If they manage to reject the null hypothesis,
they can accept the “alternative hypothesis”, i.e., that there is a
difference between the two interventions.
Blinding
RCTs can be, but are not always, blinded. Blinding means that
someone who plays an active part in the trial does not know what
treatment (new intervention, gold standard or placebo) has been
assigned to each participant. Trials can be single-blinded, double-
blinded or even triple-blinded depending on how many types of
people involved in the trial are blinded. For example, the
participant could be blinded and not know what intervention they
are assigned to. Or the medical doctor who deals with all the
participants might not know to which intervention each participant
is assigned. Or the statistician who reviews all the datasets and
performs the statistical analysis might not know which group of
participants has been assigned to which intervention. As you can
imagine, if the participants are blinded, then there is less
likelihood that they will complain of symptoms or side-effects that
are known to be associated with either the new intervention, or
the gold standard, or placebo. Similarly, a blinded doctor is less
likely to assess patients in a biased way. To avoid the bias the
statistical tests should be chosen prior to starting the RCT along
with the rationale given for choosing them). Everybody has biases
– even you!
Random Allocation
RCTs by definition, randomly allocate participants to the different
arms. This is designed to mimic chance, and to ensure that there
is no difference between groups. A good trial published in a
journal will show the characteristics of the various intervention
groups summarised (usually in a table) and compared (often with
p values and confidence intervals, though not always) to prove to
the reader that there are no differences at baseline.
Randomisation does not mean assigning alternate treatments to
every second patient, nor assigning intervention A to patients who
present on Mondays, Wednesdays and Fridays and intervention B
to all others; if a well-meaning, but biased, physician wants his
favourite patient to be assigned to intervention A he can tell that
patient to come in on the day that intervention will be assigned;
this is known as selection bias. Randomisation is designed to
prevent biases, as well as to ensure “same-ness” between the
assignment groups. The best method of randomisation is to use
computer software to generate a sequence of random numbers,
where each number refers to one of the interventions.
Sample Size Calculations
Calculating the number of patients needed for a trial is important.1
If you can show that a new intervention is statistically significantly
better than the old intervention by randomising fifty patients, you
can avoid the expense of randomising and treating one hundred
patients (which would also be unethical if the new treatment was
beneficial). On the other hand twenty-five patients might not be
enough to detect a statistically significant difference, even if a
difference truly does exist (this is a type II error). In other words
the ‘power’ of the study was too low to show the difference. To
avoid costly errors when planning a trial, trialists use a nomogram
(e.g., Altman’s nomogram2) inputting three pieces of information:
the required level of statistically significant difference (usually to
0.05 or 0.01 level); a pre-determined difference between the
interventions that would be clinically relevant; and the power of
the study (the risk of making a type 2 error), which the trialists
choose to set at a pre-determined level (often around 80%). This
nomogram then calculates how many patients are needed to
show this predetermined clinical difference, at the predetermined
power and level of statistical significance. This is the total number
of participants needed to complete the trial. Most trialists will try
to recruit more than this, to allow for drop-outs during the study
period. Sample sizing software can also be used to calculate the
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optimal sample sizes, and simple algorithms can be used to
produce sample size estimates.
The number of participants assigned to each individual
intervention will also depend on the study design. The most
common trial uses approximately the same number of participants
in each arm, a 1:1 trial. But, if the trialists decide that they want
two participants to receive intervention A for every one participant
that receives intervention B; this is a 2:1 trial – then, advanced
statistical input is required and your nomogram calculations are
not appropriate. Interestingly, most large trials will not have exactly
the same number of participants in each arm; this is due to the
use of random number sequences. However, there are methods of
randomisation available to statisticians that can be used to ensure
equal numbers per arm of the trial, e.g., the use of ‘blocking’.
CONSORT
The CONSORT statement3,4 (www.consort-statement.org, where
CONSORT stands for CONsolidated Standards of Reporting
Trials) was originally published in 2001 simultaneously in The
Journal of the American Medical Association (JAMA), Annals of
Internal Medicine, the Lancet and BMC BioMed Central, and an
additional “Explanation and Elaboration Document”4 explaining
how to use CONSORT. The aim of CONSORT is to standardise
reporting of the methods and results of RCTs. The rationale is that
if the study is reported properly, it was probably conducted
properly. Currently, most journals require that manuscripts
reporting RCTs follow CONSORT guidelines. These guidelines
include 22 points and a flow-diagram summarising the
participation of patients during enrolment, intervention allocation,
follow-up, and analysis in the RCT. One of the benefits of the
flow-diagram is that readers can immediately identify if there was
a significant drop-out in any of the arms of the trial (maybe in the
new intervention arm, as participants found the side-effects
intolerable, for example). Also, it helps the reader to identify if
intention-to-treat analyses were really used to analyse both the
efficacy and the side-effects profiles of the interventions being
studied. Intention-to-treat analyses means that the effects of the
intervention are studied in the group that was randomised to that
intervention; so even drop-outs are still included in the analyses. If
drop-outs are excluded from analyses, it could potentially over-
estimate the treatment effect of the intervention as well as under-
report the side-effects experienced.
RCT Registration
Currently, anyone hoping to conduct a RCT is encouraged to
register it. This helps to ensure that the results of “negative” as
well as “positive” trials are disseminated – the publication bias for
“positive” trials is well recognised although, of course, it is
unethical to conduct a trial and fail to disseminate the information,
even if its results are “negative”. Central registration of RCTs also
helps to prevent duplication of trials studying a particular
intervention and helps comparison of results, in the event of
duplication. As a resource for identifying both “positive” and
“negative” trials, it also facilitates authors of systematic reviews to
identify all trials and to produce unbiased systematic reviews.
Registration of trials when they begin is a requirement for
publication of the results in certain journals, e.g., The British
Medical Journal (BMJ). There are two large on-line sites for RCT
registration; one is run by the National Institutes of Health in the
USA (www.clinicaltrials.gov) and the other is the Cochrane Central
Register of Controlled Trials, run by the Cochrane Collaboration in
the UK (www.cochrane.org).
A properly-conducted trial is one of the highest levels of evidence,
second only to systematic reviews, in the Hierarchy of Evidence5
available to medical decision-makers today (i.e., you!). We hope
that this tutorial helps you to evaluate RCTs and to make informed
decisions. Maybe in the future, you will partake in, design or
conduct your own RCTs! For further information on RCTs, see the
sources below.
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Table 1 Glossary of terms




all participants are analysed in their original groups even
if drop out or cross over occurs
Nomogram a graph used to calculate sample size
Sample Size The number of participants required to detect a true
difference between two interventions, if such a
difference exists in the population
Type I error A statistically significant difference is found between
groups which is not true for the population
Type II error No statistically significant difference is found between
the groups though there is a real difference in the
population; this is because the sample sizes were too
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